<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558453</url>
  </required_header>
  <id_info>
    <org_study_id>OXALI_L_04946</org_study_id>
    <nct_id>NCT01558453</nct_id>
  </id_info>
  <brief_title>Oxaliplatin for Children With Solid Tumors</brief_title>
  <official_title>Phase II Study With Oxaliplatin In Children With Relapsed/Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidnei Epelman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Santa Marcelina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pediatric neoplastic response to chemotherapy
      proposed and evaluate sensitivity to oxaliplatin through immunohistochemistry ERCC-1
      expression analysis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine pediatric neoplastic response to proposed chemotherapy. Evaluate sensitivity to oxaliplatin through immunohistochemistry ERCC-1 expression analysis.</measure>
    <time_frame>Up 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define cumulative toxicity after oxaliplatin multiple cycles in this population. Evaluate relation between time exposure to the drug (number of cycles) and response (antitumor effect x response).</measure>
    <time_frame>Up 2 years</time_frame>
    <description>Determine response time and overall survival in these patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Relapsed Solid Tumor</condition>
  <condition>Refractory Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Eloxatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.
NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30).</description>
    <arm_group_label>Eloxatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≤ 21 years old at the time of cancer diagnosis.

          2. Confirmed histological diagnosis - every patient, except brains tumor, or optic
             pathway glioma, should have one of the following histological diagnosis:

               -  Ewing´s sarcoma/PNET

               -  Osteosarcoma

               -  Soft tissue sarcoma/rhabdomyosarcoma

               -  Wilms tumor

               -  Neuroblastoma

               -  Retinoblastoma

               -  Low grade astrocytoma

               -  High grade astrocytoma/GBM

               -  Ependymoma

               -  Germ cell tumor Other rare tumors such as - hepatocellular carcinoma, pediatric
                  colorectal carcinoma, renal cell carcinoma, adrenocortical carcinoma and
                  nasopharyngeal carcinoma.

          3. All subjects should have measurable disease, at least in one dimension, 20mm minimum,
             or presence of neoplastic cell in cephalorachidian fluid.

          4. All patients must have a life expectancy ≥ 8 weeks, with PS Karnofsky ≥50 for patients
             with ≥ 10 years old and PS Lansky ≥50 for patients &lt; 10 years old.

          5. Previous treatment:

               -  at least 3 weeks without chemotherapy.

               -  at least 6 months after spine and brain radiation.

               -  it is allowed corticosteroids in patients with CNS tumor, but it is recommended
                  to have stable doses or reducing the dose 7 days before protocol treatment.

               -  there´s no limit of drugs or chemotherapy used previously, except oxaliplatin.

          6. Adequate function as define by:

               -  Hematologic: neutrophil &gt; 1000/mm³, platelet &gt; 75000/mm³ and hemoglobin &gt; 8 g/dL.

               -  Renal - creatinine according to:

             Age ≤ 5 anos Cr ≤ 0,8 mg/dL 5 &lt; age &lt; 10 Cr ≤ 1,0 mg/dL 10 &lt; age ≤ 15 Cr ≤ 1,2 mg/dL &gt;
             15 years Cr ≤ 1,5 mg/dL

               -  Hepatic: total bilirubin ≤ 3 mg/dL.

               -  Neurologic: patients should seizure control.

          7. Legal representative (father, mother or tutor) or subject (if &gt;18 years old) must sign
             and date Informed Consent Form (ICF), after have being informed about relevant aspects
             regarding study participation.

          8. For female patients of childbearing age: Presence of a negative pregnancy test within
             7 days prior to day 0.

          9. Patient must agree in use effective contraception if procreative potential exists. Use
             of reliable means of contraception (e.g. hormonal contraceptive, patch, vaginal ring,
             intrauterine device, physical barrier, abstinence) for subjects of reproductive
             potential (males and females) is required during study treatment and for 3 months
             following last dose of study drug

         10. It should not have known curative treatment option and no proved therapy that
             increased survival with quality of life.

        Exclusion Criteria:

          1. Oxaliplatin previous use.

          2. Another chemotherapy or experimental drug, simultaneously.

          3. If female, pregnant or lactating.

          4. Active infection.

          5. Any serious existent condition that could affect, in adverse way, subjet's capacity to
             be treat according to protocol.

          6. Any condition, therapy, or medical condition, which, in the opinion of the attending
             physician could represent a risk for the patient or adversely affect the study
             objectives.

          7. Use of investigational drug &lt; 30 days before entering study.

          8. Medical history with:

               -  severe renal insufficiency;

               -  known hypersensitiveness to platine;

               -  myelosuppression;

               -  peripheral sensory neuropathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidnei Epelman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Santa Marcelina Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Santa Marcelina Hospital</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>08270070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2012</study_first_submitted>
  <study_first_submitted_qc>March 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Santa Marcelina</investigator_affiliation>
    <investigator_full_name>Sidnei Epelman</investigator_full_name>
    <investigator_title>Director of Pediatric Oncology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

